In cancer, angiogenesis is a double-edged sword. Tumors require a blood supply to grow beyond a certain size, making angiogenesis a critical step in tumor progression. Cancer cells often secrete large amounts of VEGF to stimulate vessel growth. Targeting angiogenesis has become a therapeutic strategy, with drugs like Bevacizumab (an anti-VEGF antibody) used to inhibit tumor vascularization.
